PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid

被引：0
|
作者：
Ankit Balhara
Saranjit Singh
机构：
[1] National Institute of Pharmaceutical Education and Research (NIPER),Department of Pharmaceutical Analysis
来源：
Pharmaceutical Research | 2021年 / 38卷
关键词：
DDI; genetic polymorphism; isoniazid; N-acetyl transferase; PBPK modeling;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1485 / 1496
页数：11
相关论文
共 50 条
  • [41] A Cocktail Interaction Study Evaluating the Drug-Drug Interaction Potential of the Perpetrator Drug ASP8477 at Multiple Ascending Dose Levels
    Treijtel, Nicoline
    Collins, Christiane
    van Bruijnsvoort, Michel
    Fuhr, Rainard
    Ernault, Etienne
    Gangaram-Panday, Shanti
    Passier, Paul
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (04): : 529 - 540
  • [42] NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population
    Lv, Xiaozhen
    Tang, Shaowen
    Xia, Yinyin
    Zhang, Yuan
    Wu, Shanshan
    Yang, Zhirong
    Li, Xiaoting
    Tu, Dehua
    Chen, Yixin
    Deng, Peiyuan
    Ma, Yu
    Chen, Dafang
    Chen, Ru
    Zhan, Siyan
    ANNALS OF HEPATOLOGY, 2012, 11 (05) : 700 - 707
  • [43] Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential
    Michael Gertz
    Catherine M. Cartwright
    Michael J. Hobbs
    Kathryn E. Kenworthy
    Malcolm Rowland
    J. Brian Houston
    Aleksandra Galetin
    Pharmaceutical Research, 2013, 30 : 761 - 780
  • [44] Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential
    Gertz, Michael
    Cartwright, Catherine M.
    Hobbs, Michael J.
    Kenworthy, Kathryn E.
    Rowland, Malcolm
    Houston, J. Brian
    Galetin, Aleksandra
    PHARMACEUTICAL RESEARCH, 2013, 30 (03) : 761 - 780
  • [45] The influence of genetic polymorphism and drug-drug interaction on antiplatelet effect in patients treated with long-term dual antiplatelet therapy
    Jeong, Y. H.
    Park, Y. H.
    Kim, I. S.
    Kwon, T. J.
    Tantry, U.
    Bliden, K. A.
    Gurbel, P. A.
    EUROPEAN HEART JOURNAL, 2011, 32 : 250 - 251
  • [46] The influence of genetic polymorphism and drug-drug interaction on antiplatelet effect in patients treated with long-term dual antiplatelet therapy
    Jeong, Y-H
    Yongwhi, P.
    In-Suk, K.
    Tae, J. K.
    Jin-Yong, H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 75 - 76
  • [47] Using semi-PBPK modeling to explore the impact of route of administration on the metabolic drug-drug interaction (DDI) between midazolam (MDZ) and erythromycin (ERY)
    Li, Mengyao
    Venitz, Jurgen
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S30 - S30
  • [48] Study on the Pharmacokinetics Drug-Drug Interaction Potential of Glycyrrhiza uralensis, a Traditional Chinese Medicine, with Lidocaine in Rats
    Tang, Jingcheng
    Song, Xiaohong
    Zhu, Min
    Zhang, Jinnan
    PHYTOTHERAPY RESEARCH, 2009, 23 (05) : 603 - 607
  • [49] The Impact of Customized Screening Intervals on the Burden of Drug-Drug Interaction Alerts: An Interrupted Time Series Analysis
    Van de Sijpe, Greet
    Walgraeve, Karolien
    Van Laer, Eva
    Quintens, Charlotte
    Machiels, Christophe
    Foulon, Veerle
    Casteels, Minne
    Van der Linden, Lorenz
    Spriet, Isabel
    JOURNAL OF MEDICAL SYSTEMS, 2024, 48 (01)
  • [50] Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 2: Investigating Interaction Potential Using a Physiologically Based Pharmacokinetic Model
    Van den Bergh, An
    Snoeys, Jan
    De Zwart, Loeckie
    Ward, Peter
    Lopez-Gitlitz, Angela
    Ouellet, Daniele
    Monshouwer, Mario
    Chien, Caly
    CLINICAL PHARMACOKINETICS, 2020, 59 (09) : 1149 - 1160
12345